Healthcare of Ontario Pension Plan Trust Fund Has $43.18 Million Stake in Johnson & Johnson (NYSE:JNJ)

Healthcare of Ontario Pension Plan Trust Fund trimmed its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 33.5% in the second quarter, Holdings Channel reports. The fund owned 243,269 shares of the company’s stock after selling 122,543 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Johnson & Johnson were worth $43,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.4% in the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after buying an additional 3,358,478 shares during the period. GQG Partners LLC lifted its stake in shares of Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after buying an additional 2,547,378 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in shares of Johnson & Johnson by 37.2% in the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after buying an additional 1,805,632 shares during the period. Swiss National Bank lifted its stake in shares of Johnson & Johnson by 14.0% in the first quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock valued at $2,020,868,000 after buying an additional 1,396,500 shares during the period. Finally, Bridgewater Associates LP lifted its stake in shares of Johnson & Johnson by 40.3% in the first quarter. Bridgewater Associates LP now owns 4,345,002 shares of the company’s stock valued at $770,065,000 after buying an additional 1,247,260 shares during the period. 68.59% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at $22,354,891.68. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at $22,354,891.68. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Insiders sold a total of 212,646 shares of company stock valued at $36,791,022 over the last quarter. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on JNJ shares. Barclays started coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price for the company. Sanford C. Bernstein dropped their price target on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Citigroup dropped their price target on shares of Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Bank of America dropped their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Finally, Morgan Stanley dropped their price target on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $181.33.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $177.01 on Thursday. The firm has a market cap of $462.79 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 3.49 and a beta of 0.57. The company has a 50 day moving average of $168.35 and a 200-day moving average of $171.28. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the business posted $2.60 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson declared that its Board of Directors has initiated a share repurchase plan on Wednesday, September 14th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.